Stocks Health care IFRX
NASDAQ · Health careInflaRx N.V. (IFRX)
InflaRx N.V. reported revenue of €29.3K in fiscal 2025, down 82.3% from a year earlier. It posted a net loss of €45.6M. At December 31, 2025 it held €16M in cash. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on March 20, 2026.
Key facts about InflaRx N.V.
- Net worth
- InflaRx N.V. has a market value (market cap) of $178.3M at the latest share price, and shareholders' equity of €7.2M on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was €29.3K (-82.3% year on year), with a net loss of €45.6M.
- Cash flow
- In fiscal 2025 operations used €35.3M of cash.
- Latest report
- The latest periodic report (annual report (foreign issuer), 20-F) was filed with the SEC on March 20, 2026 and covers the period to December 31, 2025. Open on SEC EDGAR
What InflaRx N.V. does
InflaRx N.V. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker IFRX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | €29.3K | -€45.6M | -€0.68 | n/a |
| 2024 | €165.8K | -€46.1M | -€0.78 | n/a |
| 2023 | €63.1K | -€42.7M | -€0.78 | n/a |
| 2022 | n/a | -€29.5M | -€0.67 | n/a |
| 2022 | n/a | -€45.6M | -€1.10 | n/a |
| 2020 | n/a | -€34M | -€1.26 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What InflaRx N.V. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 6, 2026
- November 3, 2026
- November 3, 2026
- October 22, 2026
- August 17, 2026Passive stake (5% or more) SCHEDULE 13G
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 6, 2026Passive stake (5% or more) SCHEDULE 13G
- August 6, 2026Form F-3 filing F-3
Insider trades
What the people running InflaRx N.V. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Who owns IFRX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Montanova Capital, LLC13G, passive with 2 related filers | 15.6% | August 14, 2026 |
| TCG Crossover GP III, LLC13G, passive with 2 related filers | 9.8% | May 12, 2026 |
| Sirenia Capital Management LP13G, passive with 1 related filers | 6.1% | August 14, 2026 |
| Fmr LLC13G, passive with 1 related filers | 5.5% | August 6, 2026 |
| Commodore Capital LP13G, passive with 3 related filers | 5.1% | August 17, 2026 |
| Dapice Joshua J.13G, passive with 25 related filers | 5.1% | May 14, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 62 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Montanova Capital, LLC | 22,933,910 | +15,000,000 |
| TCG Crossover Management, LLC | 14,500,000 | new |
| Fmr LLC | 8,163,341 | new |
| Commodore Capital LP | 7,300,000 | new |
| Kalehua Capital Management LLC | 5,795,538 | new |
| Spruce Street Capital LP | 5,352,198 | new |
| 683 Capital Management, LLC | 5,065,000 | +1,750,000 |
| Farallon Capital Management, L.L.C. | 3,325,000 | new |
| Stempoint Capital LP | 3,228,255 | new |
| Great Point Partners LLC | 3,046,557 | new |
| ADAR1 Capital Management, LLC | 3,000,000 | +2,841,729 |
| Ameriprise Financial Inc | 2,572,799 | new |
| Woodline Partners LP | 2,105,486 | new |
| Squadron Capital Management LLC | 2,000,000 | new |
| Eversept Partners, LP | 1,304,069 | -454,504 |
| Franklin Resources Inc | 1,036,118 | new |
| Morgan Stanley | 915,614 | -259,962 |
| Jefferies Financial Group Inc. | 775,349 | new |
| Marshall Wace, Llp | 711,296 | +156,932 |
| Millennium Management LLC | 567,049 | new |
Insiders
Questions about IFRX
What does InflaRx N.V. do?
InflaRx N.V. is a company in the Health care sector, listed on NASDAQ as IFRX. Its shares trade on NASDAQ under the ticker IFRX.
What is InflaRx N.V.'s net worth?
InflaRx N.V. has a market value (market cap) of $178.3M at the latest share price, and shareholders' equity of €7.2M on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is InflaRx N.V. profitable?
No. In fiscal 2025 it reported a net loss of €45.6M on revenue of €29.3K.
How much revenue does InflaRx N.V. make?
In fiscal 2025 InflaRx N.V. reported revenue of €29.3K. That is 82.3% less than a year earlier.
When did InflaRx N.V. last report?
Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on March 20, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the foreign issuer update from November 6, 2026.
Similar companies
Compare IFRX with
Follow IFRX
Get an email when InflaRx N.V. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values InflaRx N.V. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.